Investigation of Cytarabine Resistance: Targeting the Cell Cycle Checkpoints and Strategies for Overcoming Resistance of Acute Myeloid Leukemia to Cytarabine

Hans Minderman, Michael A. Caligiuri, John Anastasi, Bayard L. Powell, Jonathan E. Kolitz, Charles A. Schiffer, Clara D. Bloomfield, Richard A. Larson, Maria R. Baer, Stephen L. George, Richard K. Dodge, Kieran L. O'Loughlin, Phase 3 study of the multidrug resistance modulator PSC-833 in previously untreated patients 60 years of age and older with acute myeloid leukemia: Cancer and Leukemia Group B Study 9720 Blood. ,vol. 100, pp. 1224- 1232 ,(2002) , 10.1182/BLOOD.V100.4.1224.H81602001224_1224_1232

Adrian M. Senderowicz, Flavopiridol: the first cyclin-dependent kinase inhibitor in human clinical trials. Investigational New Drugs. ,vol. 17, pp. 313- 320 ,(1999) , 10.1023/A:1006353008903

Adrian M Senderowicz, Donna Headlee, Sherman F Stinson, Richard M Lush, Nelson Kalil, Lourdes Villalba, Kimberly Hill, Seth M Steinberg, William D Figg, Anne Tompkins, Susan G Arbuck, Edward A Sausville, Phase I trial of continuous infusion flavopiridol, a novel cyclin-dependent kinase inhibitor, in patients with refractory neoplasms. Journal of Clinical Oncology. ,vol. 16, pp. 2986- 2999 ,(1998) , 10.1200/JCO.1998.16.9.2986

C Didier, C Cavelier, M Quaranta, M-O Galcera, C Demur, G Laurent, S Manenti, B Ducommun, G2/M checkpoint stringency is a key parameter in the sensitivity of AML cells to genotoxic stress. Oncogene. ,vol. 27, pp. 3811- 3820 ,(2008) , 10.1038/SJ.ONC.1211041

Raymond P. Perez, Lionel D. Lewis, Andrew P. Beelen, Anthony J. Olszanski, Nicholas Johnston, C. Harker Rhodes, Bernard Beaulieu, Marc S. Ernstoff, Alan Eastman, Modulation of Cell Cycle Progression in Human Tumors: A Pharmacokinetic and Tumor Molecular Pharmacodynamic Study of Cisplatin Plus the Chk1 Inhibitor UCN-01 (NSC 638850) Clinical Cancer Research. ,vol. 12, pp. 7079- 7085 ,(2006) , 10.1158/1078-0432.CCR-06-0197

Hagop Kantarjian, Susan O'Brien, Jorge Cortes, William Wierda, Stefan Faderl, Guillermo Garcia-Manero, Jean-Pierre Issa, Elihu Estey, Michael Keating, Emil J. Freireich, Therapeutic advances in leukemia and myelodysplastic syndrome over the past 40 years Cancer. ,vol. 113, pp. 1933- 1952 ,(2008) , 10.1002/CNCR.23655

Alan Ashworth, A Synthetic Lethal Therapeutic Approach: Poly(ADP) Ribose Polymerase Inhibitors for the Treatment of Cancers Deficient in DNA Double-Strand Break Repair Journal of Clinical Oncology. ,vol. 26, pp. 3785- 3790 ,(2008) , 10.1200/JCO.2008.16.0812

Sean Vance, Erqi Liu, Lili Zhao, Joshua D. Parsels, Leslie A. Parsels, Jeffery L. Brown, Jonathan Maybaum, Theodore S. Lawrence, Meredith A. Morgan, Selective radiosensitization of p53 mutant pancreatic cancer cells by combined inhibition of Chk1 and PARP1. Cell Cycle. ,vol. 10, pp. 4321- 4329 ,(2011) , 10.4161/CC.10.24.18661

William G. Kaelin, The Concept of Synthetic Lethality in the Context of Anticancer Therapy Nature Reviews Cancer. ,vol. 5, pp. 689- 698 ,(2005) , 10.1038/NRC1691

N Bucher, C D Britten, G2 checkpoint abrogation and checkpoint kinase-1 targeting in the treatment of cancer British Journal of Cancer. ,vol. 98, pp. 523- 528 ,(2008) , 10.1038/SJ.BJC.6604208